Conestoga Capital Advisors LLC lowered its stake in shares of Alpha Teknova, Inc. (NASDAQ:TKNO - Free Report) by 32.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 305,129 shares of the company's stock after selling 148,770 shares during the period. Conestoga Capital Advisors LLC owned approximately 0.57% of Alpha Teknova worth $1,477,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System bought a new stake in Alpha Teknova during the first quarter worth $35,000. FourWorld Capital Management LLC bought a new stake in Alpha Teknova in the first quarter worth about $135,000. Redmile Group LLC grew its position in shares of Alpha Teknova by 6.5% during the 1st quarter. Redmile Group LLC now owns 171,453 shares of the company's stock valued at $434,000 after acquiring an additional 10,448 shares during the period. Finally, Roubaix Capital LLC purchased a new stake in shares of Alpha Teknova during the 3rd quarter worth approximately $2,015,000. 13.81% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Stephens reissued an "overweight" rating and issued a $5.00 target price on shares of Alpha Teknova in a research report on Wednesday, July 10th.
Read Our Latest Research Report on TKNO
Alpha Teknova Stock Performance
Shares of NASDAQ TKNO traded up $0.26 during midday trading on Friday, hitting $7.06. The company's stock had a trading volume of 137,833 shares, compared to its average volume of 223,276. Alpha Teknova, Inc. has a one year low of $1.15 and a one year high of $7.49. The stock has a fifty day moving average price of $5.28 and a 200 day moving average price of $3.31. The company has a current ratio of 4.76, a quick ratio of 3.28 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $376.30 million, a price-to-earnings ratio of -7.80 and a beta of 0.43.
Alpha Teknova (NASDAQ:TKNO - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. Alpha Teknova had a negative return on equity of 37.00% and a negative net margin of 98.08%. The business had revenue of $9.61 million for the quarter, compared to analyst estimates of $9.50 million. During the same period in the prior year, the company earned ($0.25) EPS. On average, research analysts forecast that Alpha Teknova, Inc. will post -0.54 EPS for the current fiscal year.
Alpha Teknova Company Profile
(
Free Report)
Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
Further Reading
Before you consider Alpha Teknova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Teknova wasn't on the list.
While Alpha Teknova currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
